Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Articles

Along with the approval, Sun Pharma is introducing an access program to assist eligible patients in starting and adhering to the treatment. 

The FDA Approves Deuruxolitinib for Severe Alopecia in Adults

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Combining electrocoagulation with pharmacotherapy significantly reduced keloid scar volume by inhibiting collagen deposition, angiogenesis, and cell proliferation.

Electroablation Plus Pharmacotherapy Leads to Reduction in Keloid Volume

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on how the publication has impacted their practice.

web thumbnail.png

Expert Reflections: Impact of Dermatology Times

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

The study highlights the need for personalized treatments, suggesting that this combination therapy is most beneficial when tailored to individual risk profiles.

Combining Microneedling and Tranexamic Acid for Melasma: Efficacy and Satisfaction

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

View

Los Angeles - Topical bleaching agents can safely treat post-inflammatory hyperpigmentation in darker skin types as long as treatment is conservative and monitored closely, says Pearl E. Grimes, M.D., director of the Vitiligo and Pigmentation Institute of Southern California.

Conservative, careful bleaching safe for darker skin